Fibrocell Announces Collaboration with Castle Creek Pharmaceuticals to Develop and Commercialize FCX-007 Gene Therapy
- Fibrocell to receive up to $135 million, including up to $30 million in upfront, near-term and development payments and a 30% gross profit share - - Fibrocell retains rights to the eligible Rare Pediatric Disease Priority Review Voucher - - Phase 3 clinical trial (DEFI-RDEB) initiation expected in second